The COVID-19 pandemic has severely impaired the overall pharmaceutical supply chain, mostly owing to the absence of workers at manufacturing sites and restrictions imposed on distribution networks. In this context, continuous manufacturing offers a viable solution given the fact that continuous processes are largely automated. In fact, the FDA (and other regulatory bodies) have also expressed interest in advocating a shift to the use of advanced manufacturing technologies, such as continuous manufacturing.
To order this 310+ page report, which features 110+ figures and 200+ tables, please visit this link
The USD 1.9 billion (by 2030) financial opportunity within the continuous manufacturing market has been analyzed across the following segments:
- Purpose of Manufacturing
- In-House
- Contract service
- Scale of Operation
- Commercial
- Preclinical / Clinical
- Type of Continuous Manufacturing related Service
- API Manufacturing
- End Product manufacturing
- Type of Drug Molecule
- Biologic
- Small Molecule
- Type of dosage form
- Solid
- Liquid
- Key Geographical Regions
- North America
- Europe
- Asia Pacific
The Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030 report features the following companies, which we identified to be key players in this domain:
- AbbVie Contract Manufacturing
- Ajinomoto Bio-Pharma Services
- Almac
- Boehringer Ingelheim BioXcellence
- Cambrex
- CordonPharma
- Hovione
- Kaneka
- Lonza
- Patheon
- SK biotek
Table of Contents
- Preface
2. Executive Summary
Introduction
- Market Landscape
- Companies with Expertise in Continuous Manufacturing in North America: Profiles
- Companies with Expertise in Continuous Manufacturing in Europe: Profiles
- Companies with Expertise in Continuous Manufacturing in Asia-Pacific: Profiles
- Recent Partnerships and Collaborations
- Recent Expansions
- Capacity Analysis
- Academic Grant Analysis
- Patent Analysis
- Initiatives of Companies with In-House Continuous Manufacturing Capabilities
- Case Study: Modular Facilities in pharmaceutical / Biotechnological Industry
- Case Study: Technology and Equipment Providers
- Case Study: Roadmap for the Adoption of Continuous Manufacturing Processes
- Market Forecast and Opportunity Analysis
- Conclusion
- Executive Insights
- Appendix 1: Tabulated Data
- Appendix 2: List of Companies and Organizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
Roots Analysis has announced the addition of “In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based Drug Discovery, Ligand Based Drug Discovery, Target Based Drug Discovery / Multi-Target Drug Design, Interface Based Drug Discovery, Approaches)” report to its list of offerings.
Presently, in silico tools / approaches are available for the identification, selection and optimization of pharmacological leads.
in fact, the predictive power of such solutions has been demonstrated to enable researchers to bypass the traditional experimental screening of billions of molecules against hundreds of biological targets, thereby, allowing significant reductions in the investment of both time and resources.
It is worth mentioning that about 30% of players presently offer end-to-end drug discovery services Over 150 software solutions are currently available for use in drug discovery Around 90 companies are currently providing software tools, web applications and other technology platforms for drug discovery.
Examples of popular softwares include (in alphabetical order) FORECASTER SUITE, MOPAC2016™, PKPlus™, REAL Space Navigator, SaaS Platform and VolSurf+.
Around 40% of the companies claim to specialize in antibodies, proteins and peptidesWithin the antibodies segment, nearly 60% of in silico service offerings are focused on the discovery of monoclonal antibodies.
Therefore, the use of technology can save time and money, while providing a far better understanding of the relationships between different formulations and processes parameters.Key Drivers, Restraints, and Opportunities of AI in Pharma and Biotech MarketAdoption of artificial intelligence (AI) in the drug discovery market in developing regions such as APAC is increasing, thanks to the expansion of pharmaceutical industries by collaborating with other industries and rise in demand to reduce drug discovery time.
Furthermore, the expansion of biotechnology industries is estimated to offer significant opportunities for the market.An estimated 50% of U.S. citizens are affected by at least one chronic condition; consequently, the pharmaceutical segment of the healthcare industry is projected to be positively impacted by the expected trend of AI adoption.All top 10 so-called giant pharma companies (namely Novartis, Roche, Pfizer, Merck, AstraZeneca, GlaxoSmithKline, Sanofi, Abbvie, Bristol-Myers Squibb, and Johnson & Johnson) have either expressly collaborated with or acquired AI technologies to take advantage of the opportunities AI brings to the table.
Industry leaders are presently focused on the development of more efficient methods, and machine learning is emerging as a possible solution.The current machine learning initiatives of the top five pharmaceutical and biotechnology companies reveal trends within the following areas:Digital coaching solutions – Utilization of web-based technologies to simulate one-on-one coaching sessions so that all patients can have the benefit of a uniquely devised medication program.For instance: Johnson & Johnson’s Patient Athlete programPersonalized medicine – Personalized medicine, also called precision medicine, maybe a medical model that separates people into different groups—with medical decisions, practices, interventions, and/or products being tailored to the individual patient supported their predicted response or risk of disease.For instance.
Unlike other applications within healthcare facilities, drug discovery seems to own a clearer path to adoption.Recently, robots became more collaborative with humans and are more easily trained by moving them through the desired task.
Over time, it seems likely that an equivalent improvement in intelligence that we have seen in other areas of AI would be incorporated into physical robots.Surgical robots initially approved in the U.S. in 2000, provided ‘superpowers’ to surgeons, improving their ability to examine, create precise and minimally invasive incisions, and stitch wounds.
Common surgical procedures using robotic surgery include gynecologic surgery, prostate surgery, and head and neck surgery.Pre Book Ai In Pharma And Biotech Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=79399=S North America to Capture Major Share of Global Market of AI in Pharma & BiotechNorth America is expected to account for a major share of the global market of AI in Pharma and Biotech due to the high prevalence of chronic diseases among the population.
Softcon Systems brings you automation solutions specific to the pharmaceutical industry – we will work with you to develop and implement ideal solutions specific to your requirements.
Automation at every point of the value chain will enable the pharma companies to get pharmaceuticals from the lab to the patient more quickly.We design systems that help pharmaceutical and biotech companies to achieve operational excellence, reduce time to market and meet all industry standards and regulations.
